Swiss pharmaceuticals giant Novartis posted Thursday a 29 percent increase in first-half net income, at $7.6 billion -- and unveiled its new chief financial officer.The Basel-based firm's net sales ...

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to a 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and Entresto ...

The pharmaceutical company raised its full-year profit guidance after continued demand for key drugs fueled growth in ...

Investing.com -- Novartis (LON: 0QLR) (SIX: NOVN) on Thursday posted a 24% rise in second-quarter net income to $4 billion, as sales of key therapies including Kisqali and Entresto drove performance ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

TSMC, which manufactures advanced semiconductors for clients including Nvidia ( NVDA) and Apple ( AAPL ), said it expects third-quarter revenue to reach between $31.8bn (£23.7bn) and $33bn, a 38% ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

A new type of medical treatment is scheduled to travel the highways and byways from headquarters in Temple in an effort to ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic ...